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ABSTRACT
Objective: Patients with chronic hepatitis B (CHB) are
reported to exhibit higher risk of subsequent
hepatocellular carcinoma (HCC). However, it remains
unclear if Chinese herbal medicine (CHM), an
important category of traditional Chinese medicine
(TCM), may lower HCC risk in this population. So this
study aimed to investigate the effects of CHM on HCC
risk among patients with CHB.
Methods: This cohort study used the Taiwanese
National Health Insurance Research Database to identify
21 020 newly diagnosed patients with CHB from 1998
to 2007. Among them, 8640 received CHM products
after CHB onset (CHM users), and the remaining 12 380
patients were designated as a control group (non-CHM
users). All enrolees were followed until the end of 2012
to measure the incidence rate and HR of HCC.
Results: During 15 years of follow-up, 371 CHM users
and 958 non-CHM users developed HCC, representing
an incidence rate of 5.28% and 10.18% per 1000
person-years, respectively. CHM users had significantly
lower HCC risk compared with non-CHM users
(adjusted HR=0.63, 95% CI 0.56 to 0.72). The
predominant effect was observed in those receiving
CHM products for more than 180 days (adjusted
HR=0.52). Some CHM products, such as Hedyotis
diffusa, Scutellaria barbata, Rehmannia glutinosa, Isatis
tinctoria, Yi Guan Jian, Xiao Chai Hu Tang, Wu Ling San
and Gan Lu Yin, were significantly associated with lower
risk of HCC.
Conclusions: The use of CHM was associated with a
significantly reduced HCC risk in patients with CHB,
which supports the integration of TCM with CHM into
clinical practice to influence a favourable prognosis.

INTRODUCTION
Hepatitis B virus (HBV) infection is a serious
global public health concern. Chronic hepatitis B (CHB) infection can lead to acute and
chronic hepatitis, liver cirrhosis, liver cancer

Strengths and limitations of this study
▪ The major strengths of this study included the
application of retrospective cohort design as well
as nationwide administrative database, which
could decrease recall and selection bias and
further provide stronger causal relationship than
case–control or cross-sectional design.
▪ This is the first report to identify the therapeutic
efficacy of Chinese herbal medicine on the subsequent risk of hepatocellular carcinoma among
patients with chronic hepatitis B.
▪ Findings were beneficial for healthcare providers
in guiding more effective treatment strategies to
improve the clinical outcomes, and also a basis
for further pharmacological investigations.
▪ Coding error of disease is a possibility while
using the administrative database.

and liver failure. Approximately 2 billion
people worldwide are reportedly infected
with HBV, and more than 350 million are
chronic carriers.1 Vaccines against HBV have
successfully reduced the incidence of HBV
in younger generations. Nucleos(t)ide analogue therapy effectively suppresses HBV replication by inhibiting HBV polymerase.2
Treatment with nucleos(t)ide analogues has
been reported to delay disease progression
in patients with CHB.3 4 A meta-analysis
reported that the use of nucleoside analogue
therapy was associated with reduced risk of
HCC in patients with CHB infection.5
However, more than 350 million patients are
still infected with HBV worldwide.6 CHB
infection causes hepatitis and also leads to
hepatic decompensation, cirrhosis and hepatocellular carcinoma (HCC).6 7
The use of complementary and complementary medicine (CAM) is commonly practiced worldwide for preventive and
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therapeutic purposes. Traditional Chinese medicine
(TCM) has been widely used in Asia for more than
2000 years. At present, TCM serves as an established
segment of the public health system in China and
Taiwan. In recent years, TCM has been gaining interest
and acceptance as a form of alternative or complementary medicine in Western countries, particularly in the
supportive and palliative care of patients with cancer. In
2007, $33.9 million was spent by adults in the USA on
CAM.8 An estimated 1.5 billion people now use Chinese
herbal medicine (CHM), an important category of
TCM, for the treatment of various diseases, including
chronic HBV infection, worldwide.9 CHM is used as a
treatment adjunct or alternative to anti-HBV drugs and
accounts for 30% to 50% of the total medicine consumption for CHB treatment.10 It is also used by 19% of
patients treated for liver cancer in Taiwan.11 Owing to its
low cost and low toxicity, about 80% of patients with
CHB in China and Taiwan have received CHM
treatment.12
A number of clinical trials have been performed to
assess the therapeutic efﬁcacy and safety of CHM products.1 13 14 On the other hand, a recent cohort study
reported that adjunctive therapy with CHM may improve
the survival of patients with liver cancer.15 Although
nucleoside analogue therapy is associated with reduced
risk of HCC in patients with CHB virus infection and
experience fewer side effects, in many cases the drug
resistance and viral variation limit their efﬁcacy as therapeutic agents for CHB.1 Therefore, development of
novel antiviral drugs and more effective therapies for
the treatment of CHB are urgently needed. Some
Chinese herbal medicines, including Chinese herbal formulas, single herbs and their active ingredients, are frequently reported to have antiviral effects in basic or
clinical studies.1 10 16 The effects of TCM on CHB, both
alone and in combination with medicines of western
origin, may indeed be effective therapeutic agents for
the treatment of CHB.1 However, no long-term
population-based nationwide study has investigated associations between the use of CHM products and the risk
of HCC among HBV-infected patients. Therefore, the
purpose of this retrospective, observational nationwide
study was to test our hypothesis that the use of CHM
reduces HCC risk in patients with CHB.

METHODS
Data sources
This retrospective cohort study collected claims data
from the Longitudinal Health Insurance Database
(LHID) of the Taiwan National Health Insurance
Administration, whose information is made available to
Taiwanese researchers. Taiwan launched the single-payer
National Health Insurance (NHI) programme in 1995
to remove ﬁnancial barriers to medical care for all legal
residents. As of 2010, over 99% of Taiwan’s population
was enrolled in this programme.17 The LHID is a
2

subdata set of the NHI programme and is made up of
1 000 000 randomly sampled people who were alive in
2000. For the present study, all medical records of these
individuals were collected from 1997 to 2012. The use of
a multistage stratiﬁed systematic sampling method
ensured that no statistically signiﬁcant differences
regarding sex or age existed between the one million
insured individuals and the general population.17 This
database contains all NHI enrolment ﬁles, claims data
and the registry for prescription drugs, providing comprehensive utilisation information for the patients
covered by the insurance programme. To date, the
authors of more than 300 published papers have used
this de-identiﬁed secondary database for their studies.
Ethical considerations
Since the LHID ﬁles contained only de-identiﬁed secondary data, the review board waived the requirement
for obtaining informed consent from the patients.
Study population
Selection of study participants is shown in ﬁgure 1. All
diagnoses in the insurance claims data were coded
according to the International Classiﬁcation of Disease,
Ninth Revision, Clinical Modiﬁcation (ICD-9-CM).
Inclusion criteria for the study cohort were patients
aged 20 years or older with newly diagnosed CHB
(ICD-9-CM codes: 070.2, 070.3 or V02.61) and treated
with nucleos(t)ide analogues, including lamiduvine, adefovir, telbivudine, entevacir or tenofovir between 1998
and 2007. The index date was deﬁned as the day of
CHB diagnosis. To reduce concerns of disease misclassiﬁcation, only those patients with at least three outpatient
visits with consistent diagnoses or those being admitted
to a hospital with a primary diagnosis of CHB within the
observational period (n=22 896) were selected. A total of
1171 patients with CHB were then excluded because
they had a prior diagnosis of HCC (ICD-9-CM: 155.0
and 155.2) as indicated by linking the patients with CHB
to the catastrophic illness registry. In Taiwan, insured
residents with major diseases (eg, cancer, autoimmune
diseases, chronic renal failure) can apply for a catastrophic illness certiﬁcate that grants exemption from
copayment. Those with a follow-up period <3 months
were also excluded (n=705). Following these exclusions,
the data from 21 020 patients with CHB were retained
for analysis.
In Taiwan, only certiﬁed practitioners of Chinese
medicine are entitled to prescribe CHM products. As
the existing rule proposes,18 the frequency of patients’
visits for TCM was used to verify the CHM exposure of
each study participant. Patients with CHB who received
CHM treatment for more than 30 days due to a diagnosis of CHB, within the follow-up period, were designated
as CHM users, whereas those treated for 30 days or less,
after the initial diagnosis of CHB were designated as
non-CHM users. Follow-up person-years (PYs) of the
non-CHM users were determined by calculating the
Tsai T-Y, et al. BMJ Open 2017;7:e014571. doi:10.1136/bmjopen-2016-014571
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Figure 1 Flow chart of selection
and follow-up of study
participants. CHB, chronic
hepatitis B; CHM, Chinese herbal
medicine; HCC, hepatocellular
carcinoma; NHI, National Health
Insurance.

time interval from the index date to the earliest diagnosis of HCC, date of withdrawal from the insurance plan
or study end-date of 31 December 2012, whichever of
these dates came ﬁrst. PYs of the CHM users were calculated from the initiation of receiving CHM products and
were corrected by immortal time bias (selection bias), as
previously described.19
Demographic characteristics and comorbidities
Demographic characteristics evaluated in this study
included age, gender, income for estimating insurance
payments and urbanisation level of participants’ residential areas. Participants monthly incomes were stratiﬁed
into three levels: ≤New Taiwan Dollar (NTD) 17 880,
NTD 17 881 –NTD 43 900, and ≥NTD 43 901.
Urbanisation was divided into three levels by population:
urban (levels 1–2), suburban (levels 3–4) and rural
(levels 5–7) areas. Level 1 refers to the ‘most urbanised’
and level 7 refers to the ‘least urbanised’ communities,
as described previously.20 Baseline comorbidities were
evaluated by using the established Charlson-Deyo
comorbidity index,21 which is based on individual
medical records 1 year prior to initial cohort entry. In
addition, medication usage was stratiﬁed into two groups
according to whether the participants had received the
nucleos(t)ide analogues for more than 1 year after the
index date.
Statistical analysis
Differences in demographic characteristics and
comorbidities of CHM users versus non-CHM users were
analysed using the χ2 test and Student’s t-test. Cox proportional hazards regression analysis was applied to
compute the HR with 95% CIs of HCC risk in association with CHM use. To test the robustness of the
Tsai T-Y, et al. BMJ Open 2017;7:e014571. doi:10.1136/bmjopen-2016-014571

association between CHM use and HCC risk, CHM users
were divided into two subgroups, one group that had
received CHM products for 30–180 days and another
group that had used CHM products for more than
180 days. We also used the Kaplan-Meier method to estimate cumulative risk of HCC between groups, and
tested the difference with the log-rank test. Analyses
stratiﬁed by age and gender were conducted using the
Cox proportional hazards regression model to assess the
relative risk of HCC between CHM users and non-CHM
users. The proportional-hazards assumption was veriﬁed
using plots of log (−log(survival function)) versus log
(time) and Schoenfeld residuals versus time. All statistical analyses were conducted using SAS V.9.3 (SAS
Institute, Cary, North Carolina, USA), and p<0.05 was
established as statistical signiﬁcance.

RESULTS
A total of 21 020 patients with CHB were identiﬁed in
the national insurance database. Of these, 8640 were
CHM users and 12 380 were non-CHM users. Table 1
shows the basic characteristics between groups.
Compared to non-CHM users, CHM users were more
likely to be women, younger, with lower monthly income
and Charlson Comorbidity Index (CCI) scores and did
not receive medications after the onset of CHB (all
p<0.001).
A total of 1329 HCC events occurred among all study
participants, including 371 non-CHM users and 958
CHM users, during follow-up of 70203.05 and 94122.45
PYs, respectively. Therefore, the incidence rate of HCC
was lower in CHM users than in non-CHM users (5.28 vs
10.18 per 1000 PYs), with an adjusted HR of 0.63 (95%
CI 0.56 to 0.72; table 2). CHM use for more than
3
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Table 1 Demographic data and comorbidity comparison
of the study participants

Variables
Age, (years)
<=50
>50
Mean (SD, SD)
Gender
Female
Male
Monthly income
Low
Median
High
Residential area
Urban
Suburban
Rural
Medication
usage
Yes
No
CCI
Mean (SD)

CHM
non-users
N=12 380 (%)
7985 (64.5)
4395 (35.5)
45.69±14.09
3741 (30.2)
8639 (69.8)
5860 (47.3)
5700 (46.0)
820 (6.6)
7084 (57.2)
2085 (16.8)
3211 (25.9)

CHM users
N=8640 (%) p Value
<0.001
6380 (73.8)
2260 (26.2)
42.13±13.17 <0.001
<0.001
3966 (45.9)
4674 (54.1)
0.52
4090 (47.3)
4011 (46.4)
539 (6.2)
0.23
5011 (58.0)
1478 (17.1)
2151 (24.9)
<0.001

736 (5.9)
11 644 (94.1)

372 (4.3)
8268 (95.7)

5.69±11.0

4.79±9.1

<0.001

CCI, Charlson Comorbidity Index; CHM, Chinese herbal medicine.

180 days was associated with a predominantly reduced
risk of subsequent HCC by a magnitude of 52% (95%
CI 0.43 to 0.62). Figure 2 presents the Kaplan-Meier estimates of cumulative incidence across the three groups
during the 15-year follow-up period, after adjusting for
patients’ age, sex, medication usage, CCI scores and
urbanisation levels. The cumulative incidence of HCC
for those receiving CHM treatment for more than
180 days was signiﬁcantly lower than for those not receiving CHM (log-rank test, p<0.001).
Regarding gender-speciﬁc risk of HCC, both female and
male CHM users showed signiﬁcantly decreased risk of
HCC, with an adjusted HR of 0.46 (95% CI 0.38 to 0.61)
and 0.70 (95% CI 0.62 to 0.82), respectively (table 3).
A signiﬁcant interaction between age and sex was noted in
association with CHM use. Therefore, a stratiﬁed analysis
by age and sex was performed to determine the effect of
CHM on HCC risk (table 3). Collectively, signiﬁcant beneﬁcial effects of CHM were observed in younger patients

with CHB, regardless of their sex. In men, decreases in
adjusted HR were greater for CHM users aged ≤50 years
(adjusted HR=0.69, 95% CI 0.56 to 0.85); in women, lower
risk of HCC was observed in patients with CHB aged
≤50 years (adjusted HR=0.33, 95% CI 0.21 to 0.55).
Table 4 lists the most commonly prescribed CHM products for treating CHB, including the HR of the 10 most
commonly prescribed single-herb and multiherb products. Eight herbal products (Hedyotis diffusa, Scutellaria
barbata, Rehmannia glutinosa, Isatis tinctoria, Yi Guan Jian,
Xiao Chai Hu Tang, Wu Ling San, Gan Lu Yin) were
associated with signiﬁcantly lower risk of HCC.
DISCUSSION
According to a comprehensive literature review, this is
the ﬁrst population-based retrospective cohort study that
provides solid evidence of the association between CHM
use and HCC risk among patients with CHB treated with
nucleos(t)ide analogues. Results of the present study
reveal that usage of prescribed CHM products by a large
number of patients after CHB diagnosis is associated
with signiﬁcantly reduced HCC risk by 37%.
Although medical guidelines do not currently recommend that complementary and/or alternative medicine
be used in treating patients with CHB; CHM products
have been commonly used worldwide for treating
various illnesses. A previous study conducted in Taiwan
reported that the overall prevalence of insurancecovered TCM use in outpatient services among patients
with liver cancer was 21%.11 Other studies have reported
that 11% of women with early-stage breast cancer,22 24%
of patients with asthma,23 24 5% of patients receiving
fracture treatment25 and 52.6% of patients with prostate
cancer had used CHM to relieve symptoms or otherwise
improve their quality of life.26 As with these diseases, the
limitations of Western medicine in curing CHB appears
to drive many patients to seek alternative treatments. We
investigated the overall effects of prescribed CHM use
on HCC risk in patients with CHB and explored the
inﬂuence of speciﬁc Chinese herbal formulas on HCC
risk. Our ﬁndings showed that nearly half (41.1%) of
the patients with CHB in Taiwan used CHM after CHB
onset. However, before this study was conducted, little
evidence existed to determine the efﬁcacy of CHM in
retarding CHB progression and HCC risk. Nucleos(t)ide
analogue therapy effectively suppresses HBV replication

Table 2 Crude and adjusted HR of HCC for patients with CHB with and without CHM usage
Patient group

Event

PYs

Incidence

Crude HR (95% CI)

Adjusted HR* (95% CI)

CHM non-users
CHM users
CHM use within 30–180 days
CHM use lasted for more than 180 days

958
371
238
133

94122.45
70203.05
38879.55
31323.50

10.18
5.28
6.12
4.25

1
0.52 (0.46 to 0.58)
0.59 (0.52 to 0.68)
0.43 (0.36 to 0.51)

1
0.63 (0.56 to 0.72)
0.73 (0.63 to 0.83)
0.52 (0.43 to 0.62)

Incidence rate is per 1000 PYs.
*Model adjusted for age, gender, urbanisation level, monthly income, medication usage and CCI scores.
CCI, Charlson Comorbidity Index; CHB, chronic hepatitis B; CHM, Chinese herbal medicine; HCC, hepatocellular carcinoma; PYs, person-years.
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Figure 2 Cumulative incidence
of HCC for patients with CHB with
and without CHM usage during
the 15-year follow-up period
(Log-rank test, p<0.001). CHB,
chronic hepatitis B; CHM,
Chinese herbal medicine; HCC,
hepatocellular carcinoma; TCM,
traditional Chinese medicine.

by inhibiting HBV polymerase.2 Treatment with nucleos
(t)ide analogues has been reported to delay disease progression in patients with CHB.27 In addition, nucleos(t)
ide analogue therapy has been reported to be associated
with reduced risk of HCC development and recurrence.28 A meta-analysis reported that use of nucleos(t)
ide analogues was associated with reduced long-term
risk of HCC in patients with CHB.5
In the present study, we found that the use of CHM
was associated with reduced risk of HCC in patients with
CHB treated with nucleos(t)ide analogues (adjusted
HR=0.63) compared to risk in control participants
without CHM use. Results of the present study demonstrated further that the association between CHM use
and subsequent risk of HCC among patients with CHB
diminished with duration of use. The adjusted HR associated with CHM use were 0.73 for a treatment duration

of 30–180 days, and 0.52 for treatment duration longer
than 180 days. Several other studies have reported that
CHM improved liver function and enhanced HBeAg
and HBsAg seroconversion rates as well as HBV DNA
clearance rates,1 which was associated with immune
system response,29 30 liver ﬁbrosis and cirrhosis,31 32 and
HBV infection.1 Four HBV proteins, including the X
protein (HBx), have been implicated in the development of HCC.33–35 Other studies have also shown that
TCM is likely to suppress HBx-mediated carcinogenesis
and metastasis.36 37
In the present study, the association between use of
CHM and risk of HCC in patients with CHB diminished
with age. The adjusted HRs associated with use of CHM
were 0.46, 0.33 and 0.55, for male patients with CHB of
all ages, younger than 50 years and older than 50 years,
respectively. This age-related interaction was likely due

Table 3 Age-specific and sex-specific incidence and adjusted HR of HCC in relation to CHM among patients with CHB
Variables
Female
<=50
>50
All
Male
<=50
>50
All

CHM non-users
Case PYs

Incidence

CHM users
Case PYs

56
169
225

16383.85
11316.90
27700.75

3.42
14.93
8.12

27
69
96

23273.49
8790.53
32064.02

312
421
733

47917.38
18504.33
66421.71

6.51
22.75
11.03

143
132
275

29922.58
8216.45
38139.03

Incidence

Crude HR (95% CI)

Adjusted HR (95% CI)

1.16
7.85
2.99

0.34 (0.22 to 0.54)
0.53 (0.40 to 0.69)
0.37 (0.29 to 0.47)

0.33* (0.21 to 0.55)
0.55* (0.40 to 0.73)
0.46† (0.38 to 0.61)

4.78
16.07
7.21

0.73 (0.60 to 0.89)
0.70 (0.58 to 0.84)
0.65 (0.57 to 0.75)

0.69* (0.56 to 0.85)
0.71* (0.58 to 0.86)
0.70† (0.62 to 0.82)

Incidence rate is per 1000 PYs.
*Model adjusted for urbanisation level, monthly income, medication usage and CCI scores.
†Model adjusted for age, urbanisation level, monthly income, medication usage and CCI scores.
CCI, Charlson Comorbidity Index; CHB, chronic hepatitis B; CHM, Chinese herbal medicine; PYs, person-years.
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Table 4 Risk of HCC in relation to the top 10 used single herb and multiherb products for patients with CHB
Chinese herbal name

Tsai T-Y, et al. BMJ Open 2017;7:e014571. doi:10.1136/bmjopen-2016-014571

Single-herb products
Pin yin nomenclature
Bai Hua She She Cao
Ban Zhi Lian
Hai Piao Xiao
Hu Zhang
Xiang Fu
Yin Chen Hao.
Shan Zha
Sheng Di Huang
Ban Lan Gen
Tian Hua Fen
Multiherb products
Pin yin nomenclature
Yi Guan Jian
Xiao Chai Hu Tang
Wu Ling San
Jia Wei Xiao Yao San
Gan Lu Hsiao Tu Tan
Gan Lu Yin
Chai Hu Ching Kan Tang
Chai Hu Shu Gan Tang
Yin chen Wu Lin San
Long Dan Xie Gan Tang

Scientific name

Hedyotis diffusa
Scutellaria barbata
Endoconcha Sepiae
Fallopia japonica
Cyperus rotundus
Artemisia capillaris
Crataegi Fructus
Rehmannia glutinosa
Isatis tinctoria
Trichosanthis kirilowii

Frequency of
prescriptions

466
596
388
452
335
283
201
374
265
369

293
695
233
1317
541
226
316
236
1032
241

Average
duration (day)

Daily
dose (g)

Crude HR
(95% CI)

Adjusted HR*
(95% CI)

7.9
6.9
11.1
8.9
7.5
9.1
8.3
11.5
11.4
10.4

16.4
8.1
13.3
6.5
6.4
8.7
8.5
5.6
7.4
4.2

0.37 (0.19 to 0.45)
0.30 (0.24 to 0.41)
1.01 (0.41 to 1.63)
0.58 (0.24 to 1.14)
0.59 (0.20 to 1.38)
0.69 (0.36 to 1.10)
0.97 (0.31 to 1.89)
0.27 (0.11 to 0.39)
0.51 (0.16 to 0.75)
1.07 (0.66 to 1.63)

0.38
0.29
1.04
0.57
0.63
0.72
0.97
0.35
0.54
1.04

(0.21 to 0.52)
(0.23 to 0.43)
(0.48 to 1.64)
(0.32 to 1.16)
(0.12 to 1.39)
(0.37 to 1.12)
(0.36 to 1.93)
(0.24 to 0.47)
(0.20 to 0.81)
(0.58 to 1.54)

8.7
6.9
8.5
9.1
7.1

6.5
2.1
7.3
5.8
7.6
8.5
6.5
4.2
6.9
4.0
5.2

0.43 (0.26 to 0.65)
0.44 (0.18 to 0.59)
0.75 (0.64 to 0.93)
0.82 (0.68 to 1.12)
0.94 (0.75 to 1.28)
0.35 (0.19 to 0.49)
0.79 (0.40 to 1.20)
0.96 (0.74 to 1.16)
0.97 (0.75 to 1.11)
0.76 (0.52 to 0.99)

0.65
0.53
0.82
0.94
0.95
0.50
0.81
0.98
1.01
0.83

(0.24 to 0.72)
(0.21 to 0.76)
(0.69 to 0.98)
(0.66 to 1.15)
(0.79 to 1.27)
(0.24 to 0.76)
(0.46 to 1.21)
(0.76 to 1.18)
(0.74 to 1.19)
(0.64 to 1.06)

6.6
7.5
8.4
7.2
6.3

*Model adjusted for age, gender, urbanisation level, monthly income, medication usage and CCI scores.
CCI, Charlson Comorbidity Index; CHB, chronic hepatitis B; HCC, hepatocellular carcinoma.
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to an increased probability of HCC in patients with CHB
of advanced age. According to a previous study of the
natural history of patients with CHB in Taiwan, the risk
of HCC in patients with CHB remains low before age
40 years, begins to rise during the 40s and increases signiﬁcantly after age 50 years.7 A meta-analysis also
reported that the risk of HCC in patients with CHB
remains low before the age of 50 years and increases signiﬁcantly after that time.5 The probability of HCC risk
increasing with advanced age may reﬂect the risk reduction associated with CHM use due to differential use of
TCM among different age groups. However, this speculation requires further empirical testing.
CHB has been treated for centuries with CHM. An estimated 1.5 billion people use CHM, an important category of TCM, for the treatment of various diseases,
including chronic HBV infection worldwide.9 Owing to
its low cost and low toxicity, about 80% of patients with
CHB in China rely on this approach.12 A number of clinical trials have been performed to assess the therapeutic
efﬁcacy and safety of CHM products in CHB treatment.
For example, CHM combined with interferon or lamivudine signiﬁcantly enhanced the antiviral activities of
these agents and, accordingly, CHM was proven to have a
beneﬁcial impact on improving liver function.10 12 At the
same time, several studies have demonstrated that CHM
use is beneﬁcial in alleviating clinical symptoms, improving quality of life and immune function, preventing
recurrence and metastasis, delaying tumour progression
and prolonging survival of patients with hepatocarcinoma.38 Studies in China have also reported that CHM
may have beneﬁcial therapeutic effects on CHB.39–41
The present study has listed the most commonly used
single-herb and multiherb products used in treating
CHB in our large cohort (table 4). The prescription
process for CHM differs from that of biomedical prescriptions in that there is no deﬁned 1:1 relationship
between the prescription and the disorder type, and
the treatment of CHB may vary according to the symptoms and signs displayed by the patient. Although some
of the herbs listed, such as Hedyotis diffusa,42 43
Scutellaria barbata,44 45 Rehmannia glutinosa,46 Isatis tinctoria,46 47 and Xiao Chai Hu Tang,48–50 have been investigated in the context of CHB or HCC, while other
herbs such as Yi Guan Jian, Wu Ling San, and Gan Lu
Yin have not been carried out. Thus, the products
listed in table 4 may still be investigated in future basic
and clinical research.
Findings of the present study have important clinical
and research implications regarding the use of CHM in
treating CHB. However, several limitations should be
noted when interpreting the results of this study. First,
we identiﬁed patients with CHB and HCC using
ICD-9-CM codes rather than laboratory data, and misclassiﬁcation is possible. To minimise this error, we
selected participants with CHB only after they were
recorded as having at least three outpatient visits and
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reporting consistent diagnoses or at least one inpatient
admission. It should also be noted that the NHI of
Taiwan randomly samples claims from hospitals, interviews patients and reviews medical charts to verify the
accuracy of medical records. Second, information on
drinking alcohol, social network relationships, coping
strategies and resources, religious beliefs and educational level or the genotypes of HBV were unavailable
from the claims data. Drinking alcohol is an important
risk factor associated with HCC development in patients
with CHB. The failure to adjust for the confounding
effect of drinking alcohol could possibly lead to biased
estimates of HCC risk in our sample. However, the sexstratiﬁed analysis supports an appreciably decreased risk
of HCC for patients with CHB receiving CHM regardless of gender, while the alcohol drinking rates for
women and men in Taiwan are 0.4% and 25%, respectively.51 This observation suggests that the confounding
effect of drinking alcohol was unlikely to compromise
the results of this study. Third, we were unable to
contact the enrolled patients directly regarding their
use of CHM products due to the anonymity of identiﬁcation numbers in the database. However, nearly 95%
of the dose frequencies in Chinese herbs are typically
used for only 1 week in clinical practice, so those who
continued to receive the same prescription for a longer
period of time were therefore likely to have used the
prescribed medication.52 Additionally, prescriptions for
medications issued before 1996 were not reﬂected in
data analysis in the present study. This omission could
possibly result in underestimating the cumulative frequencies and may have weakened the effect of the speciﬁed CHM products. Fourth, though the multivariate
analysis applied in this study did consider the impact of
nucleos(t)ide analogue, to test the robustness of the
present ﬁndings, a sensitivity analysis limited to those
patients with CHB with CHM usage but without receiving any nucleos(t)ide analogue was done and revealed
that the protective beneﬁts of CHM were still in effect
(adjusted HR=0.65; 95% CI=0.55 to 0.71). These limitations notwithstanding, the strengths of this study must
also be acknowledged, including the immediate availability of data, the comprehensiveness of the database
and the statistical power derived from the large-sized
sample. In addition, this retrospective 15-year cohort
study allowed us to examine in detail the associations
between CHM usage and HCC risk, and the corresponding ﬁndings may serve as a reference for future
studies.
In conclusion, the results of this 15-year follow-up
cohort study suggest that the integration of CHM during
treatment of CHB is associated with a 37% lower risk of
developing HCC compared to risk among non-CHM
users. Results of this study may serve as a reference for
healthcare providers to help establish more effective
therapeutic interventions to improve the prognosis of
patients with CHB.
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